Kodiak Sciences Inc.
KOD
Classement en actions
#3086
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Prix de l'action
$93.69
Capitalisation boursière
$5.89B
Changement (1 jour)
2.56%
Changement (1 an)
429.32%
Pays
US
Échange Kodiak Sciences Inc. (KOD)
Catégorie
Healthcare
Historique des divisions d’actions pour Kodiak Sciences Inc. (KOD)
L’action Kodiak Sciences Inc. (symbole : KOD) a subi un total de 1 divisions.
La division la plus récente a eu lieu le Feb 23, 2022.
Une action KOD achetée avant le Feb 23, 2022 équivaudrait aujourd’hui à 5 actions KOD.
La division la plus récente a eu lieu le Feb 23, 2022.
Une action KOD achetée avant le Feb 23, 2022 équivaudrait aujourd’hui à 5 actions KOD.
Liste des divisions d’actions
| Année | Division | Multiplicateur | Multiplicateur cumulatif |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Divisions d’actions d’entreprises similaires ou concurrentes
| Entreprise | Nombre de divisions d’actions | Multiplicateur cumulatif | Pays |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
